These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 17375304)

  • 1. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
    Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
    Choi DR; Yoon SN; Kim HS; Kim JH; Kim KY; Kim BC; Choi YK; Kim JB; Han B; Song HH; Zang DY
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):639-43. PubMed ID: 25630415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
    Santini D; Vincenzi B; La Cesa A; Caricato M; Schiavon G; Spalletta B; Di Seri M; Coppola R; Rocci L; Tonini G
    Oncology; 2005; 69(1):27-34. PubMed ID: 16088232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
    Sato Y; Ohnuma H; Hirakawa M; Takahashi M; Osuga T; Okagawa Y; Murase K; Takada K; Kawano Y; Iyama S; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Okita K; Mizuguchi T; Furuhata T; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):587-94. PubMed ID: 25577134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
    Zhou JF; Bai CM; Cheng YJ; Jia N; Shao YJ; Chen SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun; 31(3):358-61. PubMed ID: 19621525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
    Meyerhardt JA; Zhu AX; Enzinger PC; Ryan DP; Clark JW; Kulke MH; Earle CC; Vincitore M; Michelini A; Sheehan S; Fuchs CS
    J Clin Oncol; 2006 Apr; 24(12):1892-7. PubMed ID: 16622264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer.
    Heras P; Kritikos K; Hatzopoulos A; Xourafas V; Kritikos N; Karagiannis S; Mitsibounas D
    Am J Ther; 2009; 16(4):319-22. PubMed ID: 19352139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
    Li W; Xu J; Shen L; Liu T; Guo W; Zhang W; Chen Z; Zhu X; Li J
    BMC Cancer; 2014 Dec; 14():986. PubMed ID: 25527007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
    Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
    Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
    Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
    Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
    Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
    J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
    Haller DG; Rothenberg ML; Wong AO; Koralewski PM; Miller WH; Bodoky G; Habboubi N; Garay C; Olivatto LO
    J Clin Oncol; 2008 Oct; 26(28):4544-50. PubMed ID: 18824706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
    Patt YZ; Lee FC; Liebmann JE; Diamandidis D; Eckhardt SG; Javle M; Justice GR; Keiser W; Salvatore JR; Bexon A; Lin E
    Am J Clin Oncol; 2007 Aug; 30(4):350-7. PubMed ID: 17762434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
    J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
    Choi CK; Chan RT; Tung SY; Lui L; Siu S; Au GK; Ho JW; Law WL
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):168-75. PubMed ID: 18155454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
    Souglakos J; Kalykaki A; Vamvakas L; Androulakis N; Kalbakis K; Agelaki S; Vardakis N; Tzardi M; Kotsakis AP; Gioulbasanis J; Tsetis D; Sfakiotaki G; Chatzidaki D; Mavroudis D; Georgoulias V
    Ann Oncol; 2007 Feb; 18(2):305-10. PubMed ID: 17079693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.